Investment & M&A transaction comps

Life Sciences Investment & M&A Transaction Comps

Explore investment and M&A transactions tagged life sciences. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.

Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.

Reviewed transactions
10
With value data
4
With revenue multiples
1
Transaction years
2005–2026

Sortable transaction comps

Life Sciences transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

4 / 10

Acquisition EV, USD

USD 29B

Investment EV, USD

-

Median EV / revenue

4.3x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

10 shown of 10 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.

Select for comparison
2026-07-20 Eurofins Undisclosed - -
Myricx Bio
Control
2026-07-06 Novartis 1,500 - -
2026-07-06 Altaris LLC 600 - -
Bio-Techne
Control
2026-06-25 Merck KGaA, Darmstadt, Germany Undisclosed - -
2026-04-27 Astorg 1,075 - -
XOMA
Control
2026-04-27 Ligand Undisclosed - -
2025-10-29 Thermo Fisher Scientific Undisclosed - -
2021-10-11 Pacira BioSciences Undisclosed - 11.0x
Celgene
Control
2019-01-03 Bristol-Myers Squibb Undisclosed - -
2005-07-01 International Flavors & Fragrances (IFF) 26,200 4.3x 18.9x

Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.

Values may be estimated, rumored, incomplete or derived from public information. Transaction comps are informational and should not be relied on as financial, investment or valuation advice.